Pfizer in Argentina
Present in Argentina since 1956, over 600 colleagues come to work every day to bring therapies to people that extend and significantly improve their lives. Our local portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. With a manufacturing plant in the City of Buenos Aires with a production capacity of 1,600 million tablets a year, we serve the local market, Latin America and other countries around the world. To learn more, please visit us at www.pfizer.com.ar
Contact:
Thames Office Park Building: Colectora Panamericana 1804, 1st floor – Sector B – South Sector
Buenos Aires, Argentina
Tel: +54 11 4788-7000
Edgardo Vázquez, Pfizer’s country manager for the Argentina Region, discusses the company’s investment strategies across their newly established business units and a few of the unique challenges presented by the…
You were General Manager of Pfizer Peru and Pfizer Venezuela before taking on the challenge of the Argentinean market. How difficult was the experience of adjusting to this unique environment?…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by…
Pfizer holds a prominent position in Portugal’s pharmaceutical landscape, especially in the hospital business and for COVID-19-related products, with the emphasis now on sustainable growth post-COVID. Paulo Teixeira, a 26-year…
Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma…
India’s pharma industry has big dreams. At the recent Annual Summit of Organisation of Pharmaceutical Producers of India (OPPI) the nation’s policymakers, academicians, industry leaders, innovators, and scientists gathered to…
Morocco is undergoing ambitious reforms, extending universal healthcare coverage to all its citizens while resolving the shortcomings laid bare during the COVID-19 pandemic. Endorsed by a USD 450 million Program-for-Results…
Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps…
As North Africa cluster lead Pfizer veteran Diego Forero heads up Morocco, Tunisia, Libya, and Algeria in addition to being the country manager for Morocco. He describes the company’s 57-year…
The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear novel. In fact, the pioneers whose discoveries enabled the…
Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time…
See our Cookie Privacy Policy Here
